Full Press Release Details
Protara Therapeutics Announces Fourth Quarter
and Full Year 2024 Financial Results and Provides a Business Update
2025 - Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for
the treatment of cancer and rare diseases, today provided a business update and announced financial results for the fourth
quarter and full year ended December 31, 2024.
"Following a year of significant progress
and execution across our pipeline, we remain well positioned to deliver on our mission to bring transformative therapies to patients with
cancer and rare diseases," said Jesse Shefferman, Chief Executive Officer of Protara Therapeutics. "Notably, supported by
positive six-month data from our Phase 2 ADVANCED-2 trial in non-muscle invasive bladder cancer (NMIBC), we continue to believe TARA-002
could represent a differentiated, meaningful addition to the treatment paradigm, both as a monotherapy and in potential combination with
other agents. We continue to expect to report initial data from 12-month evaluable patients in our ADVANCED-2 trial by mid-year."
Mr. Shefferman added, "Beyond our NMIBC
program, we remain on track to commence our pivotal THRIVE-3 trial of intravenous (IV) Choline Chloride in the first half of the year.
We also look forward to providing an interim update from our ongoing Phase 2 STARBORN-1 trial of TARA-002 in lymphatic malformations (LMs)
by the end of the first half of 2025. With our cash runway extending into 2027, we look forward to achieving many critical milestones
across all of our development programs as we work to deliver new treatment options to patients in need."
Choline Chloride for Patients on Parenteral Support (PS)
Quarter and Full Year 2024 Financial Results
TARA-002 is an investigational cell therapy in development
for the treatment of NMIBC and of LMs, for which it has been granted Rare Pediatric Disease Designation by the U.S. Food and Drug Administration.
TARA-002 was developed from the same master cell bank of genetically distinct, group A Streptococcus pyogenes as OK-432, a broad immunopotentiator
marketed as Picibanil in Japan by Chugai Pharmaceutical Co., Ltd. Protara has successfully shown manufacturing comparability between
TARA-002 and OK-432.
When TARA-002 is administered, it is hypothesized
that innate and adaptive immune cells within the cyst or tumor are activated and produce a pro-inflammatory response with release of cytokines
such as tumor necrosis factor (TNF)-alpha, interferon (IFN)-gamma IL-6, IL-10, IL-12. TARA-002 also directly kills tumor cells and triggers
a host immune response by inducing immunogenic cell death, which further enhances the antitumor immune response.
About Non-Muscle Invasive Bladder Cancer (NMIBC)
Bladder cancer is the 6th most common cancer in
the United States, with NMIBC representing approximately 80% of bladder cancer diagnoses. Approximately 65,000 patients are diagnosed
with NMIBC in the United States each year. NMIBC is cancer found in the tissue that lines the inner surface of the bladder that has not
spread into the bladder muscle.
About Lymphatic Malformations (LMs)
LMs are rare, congenital malformations of lymphatic
vessels resulting in the failure of these structures to connect or drain into the venous system. Most LMs are present in the head and
neck region and are diagnosed in early childhood during the period of active lymphatic growth, with more than 50% detected at birth and
90% diagnosed before the age of three years. The most common morbidities and serious manifestations of the disease include compression
of the upper aerodigestive tract, including airway obstruction requiring intubation and possible tracheostomy dependence; intralesional
bleeding; impingement on critical structures, including nerves, vessels, lymphatics; recurrent infection, and cosmetic and other functional
About IV Choline Chloride
IV Choline Chloride is an investigational, intravenous
phospholipid substrate replacement therapy in development for patients receiving parenteral support (PS). Choline is a known important
substrate for phospholipids that are critical for healthy liver function that also play an important role in modulating gene expression,
cell membrane signaling, brain development and neurotransmission, muscle function, and bone health. PS patients are unable to synthesize
choline from enteral nutrition sources, and there are currently no available PS formulations containing choline. Approximately 80% of
patients dependent on PS are choline-deficient and of those approximately 63% have some degree of liver dysfunction, which can lead to
hepatic failure. Every year in the U.S. there are approximately 90,000 people who require PS at home and of those approximately 30,000
are on long-term PS. IV Choline Chloride has the potential to become the first U.S. Food and Drug Administration (FDA) approved IV choline
formulation for PS patients. It has been granted Orphan Drug Designation by the FDA for the prevention and/or treatment of choline deficiency
in patients on long-term PN and been granted Fast Track Designation as a source of choline when oral or enteral nutrition is not possible,
insufficient, or contraindicated. The U.S. Patent and Trademark Office has issued us a U.S. patent claiming a choline composition and
a U.S. patent claiming a method for treating choline deficiency with a choline composition, each with a term expiring in 2041.
About Protara Therapeutics, Inc.
Protara is a clinical-stage biotechnology company
committed to advancing transformative therapies for people with cancer and rare diseases. Protara's portfolio includes its lead
candidate, TARA-002, an investigational cell-based therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC)
and lymphatic malformations (LMs). The Company is evaluating TARA-002 in an ongoing Phase 2 trial in NMIBC patients with carcinoma in
situ (CIS) who are unresponsive or na ve to treatment with Bacillus Calmette-Gu rin (BCG), as well as a Phase 2 trial in pediatric
patients with LMs. Additionally, Protara is developing IV Choline Chloride, an investigational phospholipid substrate replacement for
patients on parenteral support who are otherwise unable to meet their choline needs via oral or enteral routes. For more information,
visit www.protaratx.com.
Forward-Looking Statements
Statements contained in this press release regarding matters that are
not historical facts are "forward looking statements" within the meaning of the Private Securities Litigation Reform Act of
1995. Protara may, in some cases, use terms such as "predicts," "believes," "potential," "proposed,"
"continue," "designed," "estimates," "anticipates," "expects," "plans,"
"intends," "may," "could," "might," "will," "should" or other
words or expressions referencing future events, conditions or circumstances that convey uncertainty of future events or outcomes to identify
these forward-looking statements. Such forward-looking statements include but are not limited to, statements regarding Protara's
intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: Protara's business strategy,
including its development plans for its product candidates and plans regarding the timing or outcome of existing or future clinical trials
(including reporting initial data from 12-month evaluable patients in mid-2025); statements related to expectations regarding interactions
with the FDA; Protara's financial position; statements regarding the anticipated safety or efficacy of Protara's product candidates;
and Protara's outlook for the remainder of the year and future periods. Because such statements are subject to risks and uncertainties,
actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that contribute to the
uncertain nature of the forward-looking statements include: risks that Protara's financial guidance may not be as expected, as well
as risks and uncertainties associated with: Protara's development programs, including the initiation and completion of non-clinical
studies and clinical trials and the timing of required filings with the FDA and other regulatory agencies; general market conditions;
changes in the competitive landscape; changes in Protara's strategic and commercial plans; Protara's ability to obtain sufficient
financing to fund its strategic plans and commercialization efforts; having to use cash in ways or on timing other than expected; the
impact of market volatility on cash reserves; failure to attract and retain management and key personnel; the impact of general U.S. and
foreign, economic, industry, market, regulatory, political or public health conditions; the impact of government laws and regulations,
including the impacts on FDA's staffing, resources and ability to timely review and process regulatory submissions and the impacts
of any executive orders or tariffs; and the risks and uncertainties associated with Protara's business and financial condition in
general, including the risks and uncertainties described more fully under the caption "Risk Factors" and elsewhere in Protara's
filings and reports with the United States Securities and Exchange Commission. All forward-looking statements contained in this press
release speak only as of the date on which they were made and are based on management's assumptions and estimates as of such date. Protara
undertakes no obligation to update any forward-looking statements, whether as a result of the receipt of new information, the occurrence
of future events or otherwise, except as required by law.
Protara Therapeutics, Inc.
Consolidated Balance Sheets
(in thousands, except share and per share data)
| December 31, | ||||||||
| 2024 | 2023 | |||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 162,798 | $ | 39,586 | ||||
| Marketable debt securities | 7,494 | 25,994 | ||||||
| Prepaid expenses and other current assets | 1,863 | 3,125 | ||||||
| Total current assets | 172,155 | 68,705 | ||||||
| Restricted cash , non-current | 745 | 745 | ||||||
| Property and equipment, net | 1,027 | 1,296 | ||||||
| Operating lease right-of-use asset | 4,255 | 5,264 | ||||||
| Other assets | 3,272 | 2,944 | ||||||
| Total assets | $ | 181,454 | $ | 78,954 | ||||
| Liabilities and Stockholders' Equity | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 4,429 | $ | 2,434 | ||||
| Accrued expenses and other current liabilities | 5,408 | 2,732 | ||||||
| Operating lease liability | 1,124 | 983 | ||||||
| Total current liabilities | 10,961 | 6,149 | ||||||
| Operating lease liability, non-current | 3,359 | 4,484 | ||||||
| Total liabilities | 14,320 | 10,633 | ||||||
| Commitments and contingencies | ||||||||
| Stockholders' Equity: | ||||||||
| Preferred stock, $0.001 par value, authorized 10,000,000 shares: | ||||||||
| Series 1 convertible preferred stock, 8,028 shares authorized at December 31, 2024 and 2023, 7,991 shares issued and outstanding as of December 31, 2024 and 2023. | - | - | ||||||
| Common stock, $0.001 par value, authorized 100,000,000 shares: | ||||||||
| Common stock, 35,044,772 and 11,364,903 shares issued and outstanding as of December 31, 2024 and 2023, respectively. | 35 | 11 | ||||||
| Additional paid in capital | 412,077 | 268,725 | ||||||
| Accumulated deficit | (244,980 | ) | (200,384 | ) | ||||
| Accumulated other comprehensive income (loss) | 2 | (31 | ) | |||||
| Total stockholders' equity | 167,134 | 68,321 | ||||||
| Total liabilities and stockholders' equity | $ | 181,454 | $ | 78,954 |
PROTARA THERAPEUTICS, INC. AND SUBSIDIARIES
Consolidated Statements of Operations and Comprehensive Loss
(in thousands, except share and per share data)
| (Unaudited) | (Audited) | |||||||||||||||
| For the Three Months Ended | For the Years Ended | |||||||||||||||
| December 31, | December 31, | |||||||||||||||
| 2024 | 2023 | 2024 | 2023 | |||||||||||||
| Operating expenses: | ||||||||||||||||
| Research and development | $ | 9,499 | $ | 6,381 | $ | 31,704 | $ | 24,989 | ||||||||
| General and administrative | 4,813 | 4,660 | 17,450 | 18,624 | ||||||||||||
| Total operating expenses | 14,312 | 11,041 | 49,154 | 43,613 | ||||||||||||
| Income (Loss) from operations | (14,312 | ) | (11,041 | ) | (49,154 | ) | (43,613 | ) | ||||||||
| Other income (expense), net: | ||||||||||||||||
| Interest and investment income | 1,156 | 820 | 4,171 | 3,193 | ||||||||||||
| Other income | 387 | - | 387 | - | ||||||||||||
| Other income (expense), net | 1,543 | 820 | 4,558 | 3,193 | ||||||||||||
| Net income (loss) | $ | (12,769 | ) | $ | (10,221 | ) | $ | (44,596 | ) | $ | (40,420 | ) | ||||
| Other comprehensive income (loss): | ||||||||||||||||
| Net unrealized gain (loss) on marketable debt securities | (27 | ) | 134 | 33 | 657 | |||||||||||
| Other comprehensive income (loss) | (27 | ) | 134 | 33 | 657 | |||||||||||
| Comprehensive income (loss) | $ | (12,796 | ) | $ | (10,087 | ) | $ | (44,563 | ) | $ | (39,763 | ) | ||||
| Net income (loss) per share attributable to common stockholders, basic and diluted | $ | (0.48 | ) | $ | (0.90 | ) | $ | (2.17 | ) | $ | (3.57 | ) | ||||
| Weighted-average shares outstanding, basic and diluted | 26,432,563 | 11,364,903 | 20,592,847 | 11,331,338 |
Protara Therapeutics